A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis

@article{Gabrio2021ABF,
  title={A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis},
  author={Andrea Gabrio},
  journal={Medical Decision Making},
  year={2021},
  volume={41},
  pages={1033 - 1048}
}
  • Andrea Gabrio
  • Published 21 November 2020
  • Medicine, Mathematics, Computer Science
  • Medical Decision Making
Patient-level health economic data collected alongside clinical trials are an important component of the process of technology appraisal. For end-of-life treatments, the modeling of cost-effectiveness data may involve some form of partitioned survival analysis, in which measures of quality of life and survival for pre- and postprogression periods are combined to generate aggregate measures of clinical benefits (e.g., quality-adjusted survival). In addition, resource use data are often collected… Expand

Figures from this paper

References

SHOWING 1-10 OF 61 REFERENCES
Bayesian models for cost-effectiveness analysis in the presence of structural zero costs
  • G. Baio
  • Computer Science, Mathematics
  • Statistics in medicine
  • 2014
Bayesian modelling for cost-effectiveness data has received much attention in both the health economics and the statistical literature, in recent years. Cost-effectiveness data are characterised by aExpand
Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.
TLDR
A coherent set of Bayesian methods to extend cost-effectiveness analyses to adjust for baseline covariates, to investigate differences between subgroups, and to allow for differences between centres in a multicentre study using a hierarchical model are proposed. Expand
A framework for cost-effectiveness analysis from clinical trial data.
TLDR
A general Bayesian framework for cost-effectiveness analysis (CEA) from clinical trial data is presented, which allows for very flexible modelling of both cost and efficacy related trial data. Expand
Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST Method
Abstract The quality of life of patients is an important component of evaluation of therapies. We present an overview of a statistical method called Q-TWiST (Quality-Adjusted Time Without SymptomsExpand
Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: a Bayesian approach.
TLDR
A Bayesian approach is developed which simultaneously models both the clinical effectiveness data and the cost data, by modelling the individual components of a clinical trial consisting of 351 patients with advanced non-small cell lung cancer comparing chemotherapy with standard palliative care. Expand
Quality adjusted survival analysis.
TLDR
Quality adjusted survival analysis is presented, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life, and shows that if the value of time spent in toxicity is greater than the time spend in relapse, it can be 95 per cent confident that chemoendocrine therapy is the preferred option. Expand
Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
TLDR
A multi-state modeling survival regression approach is compared to partitioned survival and Markov decision-analytic modeling for chronic lymphocytic leukemia, and it is illustrated that it is imperative to check whether assumptions are realistic, as different model choices can influence clinical and cost-effectiveness results. Expand
A Bayesian framework for health economic evaluation in studies with missing data
TLDR
A Bayesian framework for CEA where outcome or cost data are missing is proposed that includes a practical, accessible approach to sensitivity analysis that allows the analyst to draw on expert opinion. Expand
Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials
TLDR
New Bayesian hierarchical models (BHMs) are developed that allow mean costs and outcomes, and also variances, to differ across clusters and conclude that ignoring clustering can lead to incorrect inferences in CEA that use CRTs. Expand
A full Bayesian model to handle structural ones and missingness in economic evaluations from individual-level data.
TLDR
The importance of adopting a comprehensive modelling approach to economic evaluations and the strategic advantages of building these complex models within a Bayesian framework are highlighted. Expand
...
1
2
3
4
5
...